Zhangzhou Pientzehuang Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jin Ming Huang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jin Ming Huang (58 yo)

5.3yrs

Görev süresi

CN¥601,700

Tazminat

Mr. Jin Ming Huang is GM & Director of Zhangzhou Pientzehuang Pharmaceutical., Ltd from July 2019. He joined the Zhangzhou Pientzehuang Pharmaceutical., Ltd in September 2006. Mr. Huang served as President...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jin Ming Huang	GM & Director	5.3yrs	CN¥601.70k	Veri yok
Haipeng Yang	Chief Accountant & Director	no data	CN¥529.50k	Veri yok
Cong Sheng Liu	Deputy GM & Director	no data	CN¥529.50k	Veri yok
Jin Cheng Chen	Chairman of the Supervisory Committee	2.4yrs	CN¥207.60k	Veri yok
Jianjun Jia	Independent Director	7.3yrs	CN¥80.00k	Veri yok
Dong Ming Hong	Director	no data	CN¥444.50k	Veri yok
Guang Pei Li	Independent Director	7.3yrs	CN¥80.00k	Veri yok
Zhi Peng Fan	Independent Director	6.7yrs	CN¥80.00k	Veri yok
Tengyun Wei	Supervisor	2.8yrs	Veri yok	Veri yok
Hong Kai Xu	Member of the Supervisory Board	7.2yrs	Veri yok	Veri yok
Shouying Du	Independent Director	2.8yrs	CN¥80.00k	Veri yok
Huang Yalong	Employee Supervisor	2.8yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600436 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Zhangzhou Pientzehuang Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.60 (vs CN¥1.44 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2024 Results on Oct 19, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Dividend sustainability

Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire Zhangzhou Mingyuan Spice Co., Ltd. from Zhangzhou State-owned Asset Investment Management Co., Ltd. for approximately CNY 250 million.

Second quarter 2024 earnings released: EPS: CN¥1.23 (vs CN¥1.27 in 2Q 2023)

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2024 Results on Aug 17, 2024

Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: EPS: CN¥1.62 (vs CN¥1.28 in 1Q 2023)

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥4.61 (vs CN¥4.10 in FY 2022)

Now 21% undervalued after recent price drop

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024

Third quarter 2023 earnings released: EPS: CN¥1.44 (vs CN¥1.22 in 3Q 2022)

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2023 Results on Oct 21, 2023

Second quarter 2023 earnings released: EPS: CN¥1.27 (vs CN¥1.04 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥1.26 (vs CN¥1.04 in 2Q 2022)

Investor sentiment improves as stock rises 15%

First quarter 2023 earnings released: EPS: CN¥1.28 (vs CN¥1.14 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥4.09 (vs CN¥4.03 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥1.22 (vs CN¥1.48 in 3Q 2021)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥4.03 (vs CN¥2.77 in FY 2020)

Now 23% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥1.48 (vs CN¥0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.94 (vs CN¥0.78 in 1Q 2020)

New 90-day high: CN¥326

Revenue misses expectations

Revenue misses expectations

Full year 2020 earnings released: EPS CN¥2.76

New 90-day high: CN¥300

New 90-day high: CN¥252

New 90-day low: CN¥212

Third quarter earnings released

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2020 Results on Oct 24, 2020

New 90-day high - CN¥208

Earnings released

Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire 29.2% stake in Longhui Pharmaceutical Co., Ltd. from Longhui Group Co., Ltd. and Jinyuan Rongtai Investment Management (Ningxia) Co., Ltd.

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2020 Results on Aug 22, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş